StockData
Northwest Biotherapeutics Inc logo

Northwest Biotherapeutics Inc (NWBO) stock

NWBOOTCPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$0.16−0.00 (-0.88%)

Close on Oct 19, 2026Market cap $254.79MP/E –Yield –

Northwest Biotherapeutics operating margin

Operating margin is operating income as a percentage of revenue.

Northwest Biotherapeutics's operating margin for the twelve months ending Jun 30, 2026 was -2316.1%. For fiscal 2025 it was -4347.9%, against -4812.4% the year before. The highest annual figure on record is -1161.0% in fiscal 2019.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-4347.9%+464.6
FY2024Dec 31, 2024-4812.4%−1939.4
FY2023Dec 31, 2023-2873.1%+1118.7
FY2022Dec 31, 2022-3991.7%+1252.2
FY2021Dec 31, 2021-5244.0%+1464.4
FY2020Dec 31, 2020-6708.4%−5547.4
FY2019Dec 31, 2019-1161.0%+8907.2
FY2018Dec 31, 2018-10068.2%+6205.0
FY2017Dec 31, 2017-16273.2%−3549.9
FY2016Dec 31, 2016-12723.3%−5461.4
FY2015Dec 31, 2015-7261.9%−305.7
FY2014Dec 31, 2014-6956.2%−99.1
FY2013Dec 31, 2013-6857.1%−1180.3
FY2012Dec 31, 2012-5676.8%+262193.2
FY2011Dec 31, 2011-267870.0%−114330.0
FY2010Dec 31, 2010-153540.0%–

Quarterly operating margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 2026-1438.0%+9843.6
Q1 FY2026Mar 31, 2026-2206.5%+2409.8
Q4 FY2025Dec 31, 2025-2009.5%+5998.7
Q3 FY2025Sep 30, 2025-7160.0%−3014.1
Q2 FY2025Jun 30, 2025-11281.7%−7857.4
Q1 FY2025Mar 31, 2025-4616.3%+927.4
Q4 FY2024Dec 31, 2024-8008.2%−4605.5
Q3 FY2024Sep 30, 2024-4145.9%−740.8
Q2 FY2024Jun 30, 2024-3424.3%+3330.4
Q1 FY2024Mar 31, 2024-5543.7%−4070.5
Q4 FY2023Dec 31, 2023-3402.7%−357.8
Q3 FY2023Sep 30, 2023-3405.2%+4176.4
Q2 FY2023Jun 30, 2023-6754.7%−2331.5
Q1 FY2023Mar 31, 2023-1473.2%+1575.5
Q4 FY2022Dec 31, 2022-3044.9%−173.7
Q3 FY2022Sep 30, 2022-7581.6%−2937.6
Q2 FY2022Jun 30, 2022-4423.3%+17742.0
Q1 FY2022Mar 31, 2022-3048.6%+373751.4
Q3 FY2021Sep 30, 2021-2871.1%−1496.9
Q4 FY2020Dec 31, 2020-4643.9%−3893.4
Q3 FY2020Sep 30, 2020-22165.3%−21054.8
Q2 FY2020Jun 30, 2020-376800.0%−375657.7
Q1 FY2020Mar 31, 2020-1374.2%+916.6
Q4 FY2019Dec 31, 2019-750.5%+1306.7
Q3 FY2019Sep 30, 2019-1110.5%+6211.1
Q2 FY2019Jun 30, 2019-1142.3%+5536.4
Q1 FY2019Mar 31, 2019-2290.9%+53884.1
Q3 FY2018Sep 30, 2018-2057.2%+27869.6
Q2 FY2018Jun 30, 2018-7321.6%+8726.2
Q1 FY2018Mar 31, 2018-6678.8%+2890.0
Q4 FY2017Dec 31, 2017-56175.0%−48768.6
Q4 FY2016Dec 31, 2016-29926.8%−23972.4
Q3 FY2016Sep 30, 2016-16047.8%–
Q2 FY2016Jun 30, 2016-9568.8%–
Q1 FY2016Mar 31, 2016-7406.4%–
Q4 FY2015Dec 31, 2015-5954.3%–

More Northwest Biotherapeutics figures

See a number that looks wrong?